
Sign up to save your podcasts
Or


Review of IMerge phase 3 data on imetelstat for lower-risk MDS and how prior therapies affect treatment outcomes, and other ASCO 2025 MDS updates with Andrew Brunner, MD.
By Rahul Banerjee, MD4.8
2727 ratings
Review of IMerge phase 3 data on imetelstat for lower-risk MDS and how prior therapies affect treatment outcomes, and other ASCO 2025 MDS updates with Andrew Brunner, MD.

140 Listeners

324 Listeners

498 Listeners

76 Listeners

120 Listeners

28 Listeners

1,142 Listeners

187 Listeners

22 Listeners

369 Listeners

52 Listeners

138 Listeners

48 Listeners

193 Listeners

29 Listeners